Y-mAbs Therapeutics (YMAB) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

YMAB Y-mAbs Therapeutics

Watchlist

7.970
+0.140+1.79%

Close Jan 2 16:00 ET

8.420
+0.450+5.65%

Post 19:10 ET

356.97MMarket Cap-14.76P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Shareholders in Y-mAbs Therapeutics (NASDAQ:YMAB) Have Lost 74%, as Stock Drops 14% This Past Week
Simply Wall StDec 25, 2024 07:32 ET
Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Y-mAbs TherapeuticsDec 23, 2024 00:00 ET
We're Hopeful That Y-mAbs Therapeutics (NASDAQ:YMAB) Will Use Its Cash Wisely
Yahoo FinanceDec 20, 2024 08:48 ET
Clear Street Launches Healthcare & Biotechnology Equity Research
BusinesswireDec 17, 2024 14:00 ET
JonesTrading Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $23
Moomoo NewsDec 13, 2024 15:31 ET · Ratings
Promising Preclinical Data on CD38-SADA Justifies Buy Rating for Y-Mabs Therapeutics
TipRanksDec 11, 2024 06:26 ET · Ratings

Comments

Jaguar8

Dec 8, 2024 18:55

NEWS SATURDAY

$Y-mAbs Therapeutics (YMAB.US)$
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
Y-mAbs Therapeutics (NASDAQ: YMAB)presented preclinical data and trial progress for its CD38-SADA platform at the 2024 ASH Annual Meeting. The preclinical data demonstrated selective binding and anti-tumor efficacy of CD38-SADA when used with Lutetium 177-DOTA in treating Non-Hodgkin Lymphoma (NHL).
The company also...

Trytosaveabit

Dec 8, 2024 15:51

Watching Monday/week 12/9! Data released Saturday and more to come Monday 12/9/24

$Y-mAbs Therapeutics (YMAB.US)$ Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting

Moomoo AI

Mar 24, 2024 10:01

Recent insider selling at Y-mAbs Therapeutics may indicate insiders believe shares are overpriced. The absence of insider purchases in the past year and low insider ownership warrant caution.

Selling US$1.9m Of Stock Was Lucrative Decision For Y-mAbs Therapeutics Insiders

Moomoo AI

Mar 3, 2024 08:57

The company's cash runway and revenue growth are positive. Its cash burn relative to market capitalisation is low, indicating potential for more cash raising with minimal dilution or borrowing. The company's cash burn is not a concern, suggesting it is well-positioned for continued growth funding.

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Easily Afford To Drive Business Growth

DCCTrader

Feb 14, 2024 12:07

$Y-mAbs Therapeutics (YMAB.US)$ 👀better to wait pullback 14.04 or less for more rewards then risk

Heat List

Overall

No Data